Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + R-ICE in Relapsed/Refractory Non-GCB DLBCL and Transformed Lymphomas
NCT04189952Phase 2Terminated
- Sponsor
- University of Miami
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), sponsored by University of Miami. Started Sep 2020; status: terminated.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04189952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189952.